Sex-Related Differences in Cardiac Channelopathies
暂无分享,去创建一个
J. Skinner | E. Behr | A. Krahn | H. Servatius | A. Medeiros-Domingo | L. Crotti | H. Tanner | C. Remme | L. Roten | P. Chevalier | B. Asatryan | K. Odening | T. Reichlin | S. Dobner | Y. Ben-Haim | L. Yee
[1] P. Schwartz,et al. Mothers with long QT syndrome are at increased risk for fetal death: Findings from a multicenter international study. , 2020, American Journal of Obstetrics and Gynecology.
[2] A. Wilde,et al. Caring for the Pregnant Woman with an Inherited Arrhythmia Syndrome. , 2020, Heart rhythm.
[3] M. Perez,et al. An International, Multicentered, Evidence-Based Reappraisal of Genes Reported to Cause Congenital Long QT Syndrome , 2020, Circulation.
[4] R. Kovacs,et al. Effect of Transdermal Testosterone and Oral Progesterone on Drug-Induced QT Interval Lengthening in Older Men: A Randomized, Double-Blind, Placebo-Controlled Crossover-Design Study. , 2019, Circulation.
[5] D. Roden,et al. Androgenic Effects on Ventricular Repolarization: A Translational Study From the International Pharmacovigilance Database to iPSC-Cardiomyocytes. , 2019, Circulation.
[6] J. Skinner,et al. Implantable cardioverter-defibrillators in previously undiagnosed patients with catecholaminergic polymorphic ventricular tachycardia resuscitated from sudden cardiac arrest. , 2019, European heart journal.
[7] G. Seemann,et al. Postpartum hormones oxytocin and prolactin cause pro-arrhythmic prolongation of cardiac repolarization in long QT syndrome type 2. , 2019, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[8] M. Borggrefe,et al. Sex-differences in short QT syndrome: A systematic literature review and pooled analysis , 2019, European journal of preventive cardiology.
[9] A. Wilde,et al. Response by Wilde and Gollob to Letter Regarding Article, "Reappraisal of Reported Genes for Sudden Arrhythmic Death: Evidence-Based Evaluation of Gene Validity for Brugada Syndrome". , 2019, Circulation.
[10] J. Healey,et al. Challenge and Impact of Quinidine Access in Sudden Death Syndromes: A National Experience. , 2019, JACC. Clinical electrophysiology.
[11] A. Wilde,et al. Pregnancy in Catecholaminergic Polymorphic Ventricular Tachycardia. , 2019, JACC. Clinical electrophysiology.
[12] F. Sacher,et al. Clinical presentation and follow-up of women affected by Brugada syndrome. , 2019, Heart rhythm.
[13] A. Medeiros-Domingo,et al. Emerging Implications of Genetic Testing in Inherited Primary Arrhythmia Syndromes , 2019, Cardiology in review.
[14] P. Schwartz,et al. Implantable cardioverter-defibrillator use in catecholaminergic polymorphic ventricular tachycardia: A systematic review. , 2018, Heart rhythm.
[15] J. Behrends,et al. Transgenic short-QT syndrome 1 rabbits mimic the human disease phenotype with QT/action potential duration shortening in the atria and ventricles and increased ventricular tachycardia/ventricular fibrillation inducibility , 2018, European heart journal.
[16] S. Priori,et al. Gender differences in patients with Brugada syndrome and arrhythmic events: Data from a survey on arrhythmic events in 678 patients. , 2018, Heart rhythm.
[17] M. Horie,et al. Sex‐Dependent Phenotypic Variability of an SCN5A Mutation: Brugada Syndrome and Sick Sinus Syndrome , 2018, Journal of the American Heart Association.
[18] G. Lip,et al. Sex differences in cardiac arrhythmia: a consensus document of the European Heart Rhythm Association, endorsed by the Heart Rhythm Society and Asia Pacific Heart Rhythm Society , 2018, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[19] A. Moss,et al. Clinical aspects of the three major genetic forms of long QT syndrome (LQT1, LQT2, LQT3) , 2018, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.
[20] J. Skinner,et al. Long QT molecular autopsy in sudden unexplained death in the young (1-40 years old): Lessons learnt from an eight year experience in New Zealand , 2018, PloS one.
[21] E. Behr,et al. The Diagnostic Yield of Brugada Syndrome After Sudden Death With Normal Autopsy. , 2018, Journal of the American College of Cardiology.
[22] S. Chugh,et al. Sex Differences in Cardiac Arrhythmias: Clinical and Research Implications , 2018, Circulation. Arrhythmia and electrophysiology.
[23] S. Viskin,et al. Long-term flecainide therapy in type 3 long QT syndrome , 2018, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[24] R. Bellazzi,et al. Hydroquinidine Prevents Life-Threatening Arrhythmic Events in Patients With Short QT Syndrome. , 2017, Journal of the American College of Cardiology.
[25] S. Priori,et al. Age of First Arrhythmic Event in Brugada Syndrome: Data From the SABRUS (Survey on Arrhythmic Events in Brugada Syndrome) in 678 Patients , 2017, Circulation. Arrhythmia and electrophysiology.
[26] K. Hodgkinson,et al. SEX-INFLUENCED MORTALITY IN THREE WELL-ASCERTAINED FAMILIES WITH CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA CAUSED BY A RYR2 P.R420W MUTATION: THE POWER OF EXTENDED FAMILY HISTORY , 2017 .
[27] X. Wehrens,et al. Circadian Variation of Ventricular Arrhythmias in Catecholaminergic Polymorphic Ventricular Tachycardia. , 2017, JACC. Clinical electrophysiology.
[28] Dan M Roden,et al. Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia: A Randomized Clinical Trial , 2017, JAMA cardiology.
[29] J. Skinner,et al. Utility of Post-Mortem Genetic Testing in Cases of Sudden Arrhythmic Death Syndrome , 2017, Journal of the American College of Cardiology.
[30] W. Shimizu,et al. Arrhythmia risk and β-blocker therapy in pregnant women with long QT syndrome , 2017, Heart.
[31] W. Berger,et al. Post-mortem whole-exome analysis in a large sudden infant death syndrome cohort with a focus on cardiovascular and metabolic genetic diseases , 2017, European Journal of Human Genetics.
[32] Jørgen K. Kanters,et al. Clinical Aspects of Type 3 Long-QT Syndrome: An International Multicenter Study. , 2016, Circulation.
[33] J. Skinner,et al. A Prospective Study of Sudden Cardiac Death among Children and Young Adults. , 2016, The New England journal of medicine.
[34] S. Priori,et al. Gene-Specific Therapy With Mexiletine Reduces Arrhythmic Events in Patients With Long QT Syndrome Type 3 , 2016, Journal of the American College of Cardiology.
[35] P. Brugada,et al. Clinical characterisation and long-term prognosis of women with Brugada syndrome , 2016, Heart.
[36] S. Tezenas du Montcel,et al. Asymmetry of parental origin in long QT syndrome: preferential maternal transmission of KCNQ1 variants linked to channel dysfunction , 2015, European Journal of Human Genetics.
[37] S. Viskin,et al. Management of Brugada Syndrome: Thirty-Three–Year Experience Using Electrophysiologically Guided Therapy With Class 1A Antiarrhythmic Drugs , 2015, Circulation. Arrhythmia and electrophysiology.
[38] E. Behr,et al. Fibrosis, Connexin-43, and Conduction Abnormalities in the Brugada Syndrome , 2015, Journal of the American College of Cardiology.
[39] Jeffrey M. Vinocur,et al. Catecholaminergic Polymorphic Ventricular Tachycardia in Children: Analysis of Therapeutic Strategies and Outcomes From an International Multicenter Registry , 2015, Circulation. Arrhythmia and electrophysiology.
[40] E. Behr,et al. Clinical Characteristics and Circumstances of Death in the Sudden Arrhythmic Death Syndrome , 2014, Circulation. Arrhythmia and electrophysiology.
[41] G. Koren,et al. How do sex hormones modify arrhythmogenesis in long QT syndrome? Sex hormone effects on arrhythmogenic substrate and triggered activity. , 2014, Heart rhythm.
[42] Guy Salama,et al. Sex differences in the mechanisms underlying long QT syndrome. , 2014, American journal of physiology. Heart and circulatory physiology.
[43] S. Priori,et al. Novel Insight Into the Natural History of Short QT Syndrome , 2014, Journal of the American College of Cardiology.
[44] P. Brugada,et al. The clinical significance of pregnancy in Brugada syndrome. , 2014, Revista espanola de cardiologia.
[45] A. Krahn,et al. Sudden cardiac death in children and adolescents between 1 and 19 years of age. , 2014, Heart rhythm.
[46] P. Brugada,et al. Safe Single‐Dose Administration of Propofol in Patients with Established Brugada Syndrome: A Retrospective Database Analysis , 2013, Pacing and clinical electrophysiology : PACE.
[47] C. Tracy,et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. , 2013, Heart rhythm.
[48] P. Schwartz,et al. Spectrum and Prevalence of Mutations Involving Brs1-through Brs12-susceptibility Genes in a Cohort of Unrelated Patients Referred for Brugada Syndrome Genetic Testing Implications for Genetic Testing , 2022 .
[49] Lia Crotti,et al. Long-QT syndrome: from genetics to management. , 2012, Circulation. Arrhythmia and electrophysiology.
[50] M. Ackerman,et al. Potential depot medroxyprogesterone acetate-triggered torsades de pointes in a case of congenital type 2 long QT syndrome. , 2012, Heart rhythm.
[51] D. Tester,et al. Cardiac channel molecular autopsy: insights from 173 consecutive cases of autopsy-negative sudden unexplained death referred for postmortem genetic testing. , 2012, Mayo Clinic proceedings.
[52] M. Zehender,et al. Estradiol promotes sudden cardiac death in transgenic long QT type 2 rabbits while progesterone is protective. , 2012, Heart rhythm.
[53] Mike Kirby,et al. ESC Guidelines on the Management of Cardiovascular Diseases During Pregnancy , 2012 .
[54] E. Kaufman,et al. Risk of Recurrent Cardiac Events After Onset of Menopause in Women With Congenital Long-QT Syndrome Types 1 and 2 , 2011, Circulation.
[55] Tachapong Ngarmukos,et al. Prevention of Ventricular Fibrillation Episodes in Brugada Syndrome by Catheter Ablation Over the Anterior Right Ventricular Outflow Tract Epicardium , 2011, Circulation.
[56] A. Shelling,et al. Prospective, population-based long QT molecular autopsy study of postmortem negative sudden death in 1 to 40 year olds. , 2011, Heart rhythm.
[57] S. Nattel,et al. Gender-related differences in ion-channel and transporter subunit expression in non-diseased human hearts. , 2010, Journal of molecular and cellular cardiology.
[58] M. Kirk,et al. Pharmacogenomics of anesthetic drugs in transgenic LQT1 and LQT2 rabbits reveal genotype-specific differential effects on cardiac repolarization. , 2008, American journal of physiology. Heart and circulatory physiology.
[59] D. Tamborero,et al. Gender differences in clinical manifestations of Brugada syndrome. , 2008, Journal of the American College of Cardiology.
[60] K. Reinier,et al. Epidemiology of sudden cardiac death: clinical and research implications. , 2008, Progress in cardiovascular diseases.
[61] E. Behr,et al. Sudden arrhythmic death syndrome: familial evaluation identifies inheritable heart disease in the majority of families. , 2008, European heart journal.
[62] M. Kirk,et al. Mechanisms of cardiac arrhythmias and sudden death in transgenic rabbits with long QT syndrome. , 2008, The Journal of clinical investigation.
[63] Derick R. Peterson,et al. Risk Factors for Aborted Cardiac Arrest and Sudden Cardiac Death in Children With the Congenital Long-QT Syndrome , 2008, Circulation.
[64] S. Priori,et al. Diagnosis and treatment of catecholaminergic polymorphic ventricular tachycardia. , 2007, Heart rhythm.
[65] Y. Kokubo,et al. Sex Hormone and Gender Difference—Role of Testosterone on Male Predominance in Brugada Syndrome , 2007, Journal of cardiovascular electrophysiology.
[66] E. Kaufman,et al. Long QT syndrome and pregnancy. , 2007, Journal of the American College of Cardiology.
[67] S. Priori,et al. Female predominance and transmission distortion in the long-QT syndrome. , 2006, The New England journal of medicine.
[68] M. Field,et al. Outcome After Implantation of a Cardioverter-Defibrillator in Patients With Brugada Syndrome: A Multicenter Study–Part 2 , 2006, Circulation.
[69] M. O'Neill,et al. Outcome After Implantation of a Cardioverter-Defibrillator in Patients With Brugada Syndrome: A Multicenter Study , 2006, Circulation.
[70] T. Saikawa,et al. Influence of Menstrual Cycle on QT Interval Dynamics , 2006, Pacing and clinical electrophysiology : PACE.
[71] A. Wilde,et al. Pathophysiological mechanisms of Brugada syndrome: depolarization disorder, repolarization disorder, or more? , 2005, Cardiovascular research.
[72] D. Tester,et al. Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing. , 2005, Heart rhythm.
[73] Borys Surawicz,et al. Differences between Ventricular Repolarization in Men and Women: Description, Mechanism and Implications , 2003, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.
[74] Calum A MacRae,et al. Risk stratification in the long-QT syndrome. , 2003, The New England journal of medicine.
[75] Li Zhang,et al. Modulating effects of age and gender on the clinical course of long QT syndrome by genotype. , 2003, Journal of the American College of Cardiology.
[76] S. Viskin,et al. Torsade de Pointes Due to Noncardiac Drugs: Most Patients Have Easily Identifiable Risk Factors , 2003, Medicine.
[77] M. Rosen,et al. Testosterone Diminishes the Proarrhythmic Effects of Dofetilide in Normal Female Rabbits , 2002, Circulation.
[78] Andrew C. Zygmunt,et al. Ionic and Cellular Basis for the Predominance of the Brugada Syndrome Phenotype in Males , 2002, Circulation.
[79] Carlo Napolitano,et al. Clinical and Molecular Characterization of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia , 2002, Circulation.
[80] D. Escande,et al. Novel SCN5A Mutation Leading Either to Isolated Cardiac Conduction Defect or Brugada Syndrome in a Large French Family , 2001, Circulation.
[81] P. Arini,et al. Sex differences on the electrocardiographic pattern of cardiac repolarization: possible role of testosterone. , 2000, American heart journal.
[82] S. Priori,et al. Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: findings from the International LQTS Registry. , 1998, Circulation.
[83] P. Kligfield,et al. QT interval-heart rate relation during exercise in normal men and women: definition by linear regression analysis. , 1996, Journal of the American College of Cardiology.
[84] S. Priori,et al. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. , 1995, Circulation.
[85] R. Prineas,et al. Sex differences in the evolution of the electrocardiographic QT interval with age. , 1992, The Canadian journal of cardiology.
[86] S. Viskin,et al. Female gender as independent risk factor of torsades de pointes during acquired atrioventricular block. , 2017, Heart rhythm.
[87] H. Huikuri,et al. J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge , 2016, Journal of arrhythmia.
[88] M. Ackerman,et al. Determinants of incomplete penetrance and variable expressivity in heritable cardiac arrhythmia syndromes. , 2013, Translational research : the journal of laboratory and clinical medicine.
[89] A. Wilde,et al. Gender differences in the long QT syndrome: effects of beta-adrenoceptor blockade. , 2002, Cardiovascular research.
[90] A. Moss,et al. Age-gender influence on the rate-corrected QT interval and the QT-heart rate relation in families with genotypically characterized long QT syndrome. , 1997, Journal of the American College of Cardiology.
[91] M. Lehmann,et al. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. , 1993, JAMA.